Dyadic announces research, license and collaboration agreement with janssen for the manufacture of therapeutic protein candidates using its c1 platform

Jupiter, fla., dec. 17, 2021 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on further improving, applying, and deploying its proprietary c1-cell protein production platform to accelerate development, lower production costs and improve the performance of protein based vaccines and therapeutics, announced that it has entered into a research, license and collaboration agreement (“agreement”) with janssen biotech, inc. (‘'janssen”), one of the janssen pharmaceutical companies of johnson & johnson. the agreement was facilitated by johnson & johnson innovation.
DYAI Ratings Summary
DYAI Quant Ranking